AstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy
This article is for subscribers only.
AstraZeneca Plc said it is withdrawing an application for European approval for an ovarian-cancer medicine following disagreement with regulatory authorities.
The decision won’t affect the ongoing development of the treatment, called cediranib, the Cambridge, England-based company said today in an e-mailed statement. The drugmaker had sought approval from the European Medicines Agency in June 2015 to sell the drug for use with platinum-based chemotherapy in adults with a type of ovarian cancer that’s relapsed.